// App-Quantinova.ai

4556 : Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).

Researchers

Presenter

  • Jose Luis Perez-Gracia

Principal Investigators

  • Rikke Helene Loevendahl Eefsen

  • Carlos A. Gomez-Roca

  • Sylvie Negrier

  • Paolo Pedrazzoli

  • Jae-Lyun Lee

  • Teresa Alonso Gordoa

  • Cristina Suarez Rodriguez

  • Begona Mellado

  • Victor Moreno

  • Alejo Rodriguez-Vida

  • Arif Hussain

  • Nicole Getzmann

  • David Dejardin

  • Christophe Boetsch

  • Anton Kraxner

  • Taner Vardar

  • Volker Teichgrber

  • Thomas Powles

Medical Centers

  • Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Herlev Hospital, Herlev, Denmark

  • Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France

  • Department of Thoracic Oncology, Centre Leon Berard, Lyon, France

  • Fondazione IRCCS Policlinico San Matteo, NICU, Pavia, Italy

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus,Barcelona,Spanien

  • Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

  • Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain

  • Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain

  • University of Maryland Cancer Center, Baltimore, MD, Roche, Basel, Switzerland

  • Roche, Biostatistics Oncology pRED, Basel, Switzerland

  • Roche Innovation Center Basel, Basel, Switzerland

  • Roche/Genentech, Basel, Switzerland

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

Locations

  • Spain

  • Canada

  • Denmark

  • France

  • Italy

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT03063762

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved